Acta Neuropathologica

, Volume 106, Issue 5, pp 441–448 | Cite as

Neuropathological analysis in spinal muscular atrophy type II

  • S. Araki
  • M. Hayashi
  • K. Tamagawa
  • M. Saito
  • S. Kato
  • T. Komori
  • Y. Sakakihara
  • T. Mizutani
  • M. Oda
Regular Paper
First Online:
Received:
Revised:
Accepted:

Abstract

We performed a neuropathological analysis, including in situ nick end labeling (ISEL) and immunohistochemistry, of two cases of clinicogenetically confirmed infantile spinal muscular atrophy (SMA) type II. Both cases showed severe reduction of the motor neurons and gliosis in the spinal cord and brain stem, although the occurrences of central chromatolysis and ballooned neurons were not frequent. Clark's and lateral thalamic nuclei, which are usually altered in SMA type I, were spared, whereas Betz cells in the precentral gyrus and large myelinated fibers in the lateral funiculus were reduced in number. Regarding apoptosis, only the younger case demonstrated a few ISEL-positive nuclei in the dorsal horn, with reduced Bcl-x expression level in the Purkinje cells. Unlike SMA type I, the expression of neurofilaments was not disturbed and the reduction in synaptophysin expression level in the anterior horn was mild. An oxidative stress-related product was deposited in atrophic motor neurons in the spinal cord, and neurons with nuclei immunoreactive for 8-hydroxy-2'-deoxyguanosine were found in the lateral thalamus. In contrast, the expression of glial glutamate transporters was not altered. These data suggest that oxidative stress and, to a lesser extent, apoptotic cell death, but not disturbed neurofilament metabolism or excitotoxicity, may be involved in neurodegeneration in SMA type II.

Keywords

Apoptosis Infantile spinal muscular atrophy In situ nick end labeling Motor neuron death Oxidative stress 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Aberfeld DC, Namba T (1969) Progressive opthalmoplegia in Kugelberg-Welander disease. Arch Neurol 20:253–256PubMedGoogle Scholar
  2. 2.
    Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH Jr (1997) Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 42:644–654PubMedGoogle Scholar
  3. 3.
    Dubowitz V (1995) Disorders of the lower motor neurone. The spinal muscular atrophy. In: Dubowitz V (ed) Muscle disorders in childhood, 2nd edn. Saunders, London, pp 325–369Google Scholar
  4. 4.
    Gardner-Medwin D, Hudgson P, Walton JN (1967) Benign spinal muscular atrophy arising in childhood and adolescence. J Neurol Sci 5:121–158CrossRefPubMedGoogle Scholar
  5. 5.
    Hayashi M, Arai N, Murakami T, Morimatsu Y, Oda M, Matsuyama H (1998) A study of cell death in Werdnig-Hoffmann disease brain. Neurosci Lett 243:117–120CrossRefPubMedGoogle Scholar
  6. 6.
    Hayashi M, Araki S, Arai N, Kumada S, Itoh M, Tamagawa K, Oda M, Morimatsu Y (2002) Oxidative stress and disturbed glutamate transport in spinal muscular atrophy. Brain Dev 24:770–775CrossRefPubMedGoogle Scholar
  7. 7.
    Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, Li H (2000) A mouse model for spinal muscular atrophy. Nat Genet 24:66–70PubMedGoogle Scholar
  8. 8.
    Ikemoto A, Hirano A, Matsumoto S, Akiguchi I, Kimura J (1996) Synaptophysin expression in the anterior horn of Werdnig-Hoffmann disease. J Neurol Sci 136:94–100CrossRefPubMedGoogle Scholar
  9. 9.
    Ikuta F, Ohama E, Nakanishi T, Mannen T, Toyokura Y (1979) Postmortem findings in a case of KW disease; presence of underdeveloped Schwann cells and axons. In: Japan Medical Research Foundation (ed) Amyotrophic lateral sclerosis. University of Tokyo Press, Tokyo, pp 277–284Google Scholar
  10. 10.
    Iwahashi h, Eguchi Y, Yasuhara N, Hanafusa T, Matsuzawa Y, Tsujimoto Y (1997) Synergistic anti-apoptotic activity between Bcl-2 and SMN implicated in spinal muscular atrophy. Nature 390:413–417CrossRefPubMedGoogle Scholar
  11. 11.
    Iwata M, Hirano A (1978) A neuropathological study of the Werdnig-Hoffmann disease. Neurol Med Chir 8:40–53Google Scholar
  12. 12.
    Kato S, Hirano A (1990) Ubiquitin and phosphorylated neurofilament epitopes in ballooned neurons of the extraocular muscle nuclei in a case of Werdnig-Hoffmann disease. Acta Neuropathol 80:334–337PubMedGoogle Scholar
  13. 13.
    Kohn R (1968) Postmortem findings in a case of Wohlfart-Kugelberg-Welander disease. Confin Neurol 30:253–260PubMedGoogle Scholar
  14. 14.
    Kumada S, Hayashi M, Mizuguchi M, Nakano I, Morimatsu Y, Oda M (2000) Cerebellar degeneration in hereditary dentatorubral-pallidoluysian atrophy and Machado-Joseph disease. Acta Neuropathol 99:48–54PubMedGoogle Scholar
  15. 15.
    Lee S, Park YD, Yen SHC, Ksiezak-Redling H, Goldman JE, Dickson DW (1988) A study of infantile motor neuron disease with neurofilament and ubiquitin immunocytochemistry. Neuropediatrics 20:107–111Google Scholar
  16. 16.
    Lefebvre S, Burglen L, Revoullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M, Paslier DL, Frezal J, Cohen D, Weissenbach J, Munnich A, Melki J (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:155–165PubMedGoogle Scholar
  17. 17.
    Merry DE, Veis DJ, Hickey WF, Korsmeyer SJ (1994) Bcl-2 protein expression is widespread in the developing nervous system and retained in the adult PNS. Development 120:301–311PubMedGoogle Scholar
  18. 18.
    Murayama S, Bouldin TW, Suzuki K (1991) Immunocytochemical and ultrastructural studies of Werdnig-Hoffmann disease. Acta Neuropathol 81:408–417PubMedGoogle Scholar
  19. 19.
    Nevo Y, Kramer U, Legum C, Shomrat R, Fatal A, Soffer D, Harel S, Shapira Y (1998) SMA type II unrelated to chromosome 5q13. Am J Med Genet 75:193–195CrossRefPubMedGoogle Scholar
  20. 20.
    Nunomura A, Perry G, Alive G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60:759–767PubMedGoogle Scholar
  21. 21.
    Osawa M, Shishikura K (1991) Werdnig-Hoffmann disease and variants. Handb Clin Neurol 15:51–80Google Scholar
  22. 22.
    Paulson GW, Liss L, Sweeney PJ (1980) Late onset spinal muscle atrophy—a sex linked variant of Kugelberg-Welander. Acta Neurol Scand 61:49–55PubMedGoogle Scholar
  23. 23.
    Rothstein JD, Kammen M van, Levey AI, Martin LJ, Kuncl RW (1995) Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38:73–84PubMedGoogle Scholar
  24. 24.
    Roy N, Mahadevan MS, McLean M, Shutler G, Yaraghi Z, Farahani R, Baird S, Besner-Johnston A, Lefebvre C, Kang X, Salih M, Aubry H, Tamai K, Guan X, Ioannou P, Crawford TO, Joung PJ de, Surh L, Ikeda J, Korneluk RG, MacKenzie A (1995) The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 80:167–178PubMedGoogle Scholar
  25. 25.
    Sayre LM, Zalasko DA, Harris PLR, Perry G, Salomon RG, Smith MA (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68:2092–2097PubMedGoogle Scholar
  26. 26.
    Shishikura K, Hara M, Sasaki Y, Misugi K (1983) A neuropathological study of Werdnig-Hoffmann disease with special reference to the thalamus and posterior roots. Acta Neuropathol (Berl) 60:99–106Google Scholar
  27. 27.
    Simic G, Seso-Simic D, Lucassen PJ, Islam A, Krsnik Z, Cviko A, Jelasic D, Barisic N, Winbland B, Kostovic I, Kruslin B (2000) Ultrastructural analysis and TUNEL demonstrate motor neuron apoptosis in Werdnig-Hoffmann disease. J Neuropathol Exp Neurol 59:398–407Google Scholar
  28. 28.
    Soler-Botija C, Ferrer I, Gich I, Baiget M, Tizzano EF (2002) Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord. Brain 125:1624–1634CrossRefPubMedGoogle Scholar
  29. 29.
    Soubrouillard C, Pellissier JF, Lepidi H, Mancini J, Rougon G, Figarella-Branger D (1995) Expression of developmentally regulated cytoskeleton and cell surface proteins in childhood spinal muscular atrophy. J Neurol Sci 133:155–163CrossRefPubMedGoogle Scholar
  30. 30.
    Tews DS, Goebel HH (1996) DNA fragmentation and bcl-2 expression in infantile spinal muscular atrophy. Neuromuscl Disord 6:265-273CrossRefGoogle Scholar
  31. 31.
    Tews DS, Goebel HH (1997) Apoptosis-related proteins in skeletal muscle fibers of spinal muscular atrophy. J Neuropathol Exp Neurol 56:150–156PubMedGoogle Scholar
  32. 32.
    Towfighi J, Young RSK, Ward RM (1985) Is Werdnig-Hoffmann disease a pure lower motor neuron disorder? Acta Neuropathol (Berl) 65:270–280Google Scholar
  33. 33.
    Toyokuni S (1999) Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int 49:91–102CrossRefPubMedGoogle Scholar
  34. 34.
    Winder TR, Auer RN (1989) Sensory neuron degeneration in familial Kugelberg-Welander disease. Can J Neurol Sci 16:67–70PubMedGoogle Scholar
  35. 35.
    Wirth B, Herz M, Wetter A, Moskau S, Hahnen E, Rudnik-Schoneborn S, Wienker T, Zerres K (1999) Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implication for genetic counseling. Am J Hum Genet 64:1340–1356PubMedGoogle Scholar
  36. 36.
    Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 93:2696–2701PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • S. Araki
    • 1
  • M. Hayashi
    • 4
  • K. Tamagawa
    • 1
  • M. Saito
    • 5
  • S. Kato
    • 2
  • T. Komori
    • 4
  • Y. Sakakihara
    • 5
  • T. Mizutani
    • 3
  • M. Oda
    • 3
  1. 1.Department of NeuropediatricsTokyo Metropolitan Neurological HospitalTokyoJapan
  2. 2.Department of NeurologyTokyo Metropolitan Neurological HospitalTokyoJapan
  3. 3.Department of Laboratory MedicineTokyo Metropolitan Neurological HospitalTokyoJapan
  4. 4.Department of Clinical NeuropathologyTokyo Metropolitan Institute for NeuroscienceTokyoJapan
  5. 5.Department of Pediatrics, School of MedicineTokyo UniversityTokyoJapan

Personalised recommendations